Gelonghui March 11 | Zhiyun Health (9955.HK) opened 5.65% higher at HK$4.3. According to the news, the company announced that the launch meeting for the Group's proprietary product “Hetangjing” dagliflozin tablets will be held on March 9, marking that the product has entered the marketing and sales stage after officially obtaining the drug registration certificate (Sinopharm license H20234636) issued by the State Drug Administration on December 13, 2023.
港股异动丨智云健康高开5.65%，血糖控制药“和唐净”进入上市销售阶段
Hong Kong stock changes丨Zhiyun Health opened 5.65%, and the blood sugar control drug “Hetang Jing” entered the marketing and sales stage
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.